Amneal Delivers On Biosimilars Ambitions With Neupogen Rival
Company Also Reveals Plans For 20-30 Generics Launches In 2022
Executive Summary
Amneal has laid out its plans to enter the US biosimilars market after receiving FDA approval for its first biosimilar, a Neupogen rival known as Releuko (filgrastim-ayow) that was developed with partner Kashiv Biosciences. Amneal also intends to launch two more biosimilars soon, along with 20-30 generics launches planned in 2022.
You may also be interested in...
Amneal Makes It Three With Pegfilgrastim Approval
Amneal has celebrated its third US biosimilar approval of 2022 with an FDA nod for its Fylnetra (pegfilgrastim-pbbk) rival to Neulasta, as the firm makes launch preparations for all three products across the second half of the year.
Amneal Sets $200m Sales Ambition For Biosimilar Trio
Amneal management has offered additional detail on the firm’s burgeoning biosimilars business, revealing a “peak” sales estimate of $200m for its current roster of three products as well as indicating plans to expand its pipeline both through licensing and internal development.
Generics Industry Braces For New Wave Of Price Pressure
With pricing pressures already creeping up in recent years, 2022 is set to see the generics industry caught in the middle as prices are further squeezed while costs continue to rise. As major players prepare to announce their first-quarter financial results, In Vivo looks at views from industry leaders on how these pressures are affecting their businesses, and how they can be expected to play out.